Anastrozole
- Generic Name
- Anastrozole
- Brand Names
- Arimidex
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N5
- CAS Number
- 120511-73-1
- Unique Ingredient Identifier
- 2Z07MYW1AZ
- Background
Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to letrozole, used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer. Anastrozole is also related to exemestane, a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated ad...
- Indication
Anastrozole is indicated as adjunct therapy in the treatment of hormone receptor-positive early breast cancer in postmenopausal women, and as a first-line treatment for hormone receptor-positive (or hormone receptor-unknown) locally advanced or metastatic breast cancer in postmenopausal women. It may also be used in the treatment of advanced breast cancer in...
- Associated Conditions
- Advanced Breast Cancer, Invasive Early Breast Cancer, Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Stage I Breast Cancer
- Associated Therapies
- -
Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480)
- First Posted Date
- 2004-04-16
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 110
- Registration Number
- NCT00081510
Anastrozole in Preventing Breast Cancer in Postmenopausal Women at Increased Risk of Breast Cancer
- First Posted Date
- 2004-03-09
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- Queen Mary University of London
- Target Recruit Count
- 3864
- Registration Number
- NCT00078832
- Locations
- 🇫🇮
Pirkanmaa Cancer Society, Tampere, Finland
🇲🇹Sir Paul Boffa Hospital, Harper Lane, Floriana, Malta
🇨🇭Inselspital Bern, Bern, Switzerland
Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole
- Conditions
- First Posted Date
- 2004-02-11
- Last Posted Date
- 2009-02-09
- Lead Sponsor
- Institute of Cancer Research, United Kingdom
- Target Recruit Count
- 2000
- Registration Number
- NCT00077168
- Locations
- 🇬🇧
Berkshire Cancer Centre at Royal Berkshire Hospital, Reading, England, United Kingdom
🇬🇧Derriford Hospital, Plymouth, England, United Kingdom
🇬🇧Poole Hospital NHS Trust, Poole Dorset, England, United Kingdom
Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer
- First Posted Date
- 2004-02-11
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 174
- Registration Number
- NCT00077025
- Locations
- 🇻🇪
Research Site, Valencia, Venezuela
S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer
- First Posted Date
- 2004-01-13
- Last Posted Date
- 2021-01-13
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 695
- Registration Number
- NCT00075764
- Locations
- 🇺🇸
Grant Medical Center Cancer Care, Columbus, Ohio, United States
🇺🇸Mount Carmel Health - West Hospital, Columbus, Ohio, United States
🇺🇸Alvin and Lois Lapidus Cancer Institute at Sinai Hospital, Baltimore, Maryland, United States
Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ
- First Posted Date
- 2003-11-06
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- Queen Mary University of London
- Target Recruit Count
- 2980
- Registration Number
- NCT00072462
- Locations
- 🇮🇪
Mid-Western Regional Hospital, Limerick, Ireland
🇬🇧Nottingham City Hospital, Nottingham, England, United Kingdom
🇬🇧Centre for Cancer Research and Cell Biology at Queen's University Belfast, Belfast, Northern Ireland, United Kingdom
Anastrozole With or Without Gefitinib in Treating Postmenopausal Women With Metastatic or Locally Recurrent Breast Cancer
- First Posted Date
- 2003-08-07
- Last Posted Date
- 2013-10-24
- Target Recruit Count
- 71
- Registration Number
- NCT00066378
- Locations
- 🇧🇪
Institut Jules Bordet, Brussels, Belgium
🇧🇪Algemeen Ziekenhuis Sint-Augustinus, Wilrijk, Belgium
🇧🇪Ziekenhuis Netwerk Antwerpen Middelheim, Antwerpen, Belgium
Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer
- First Posted Date
- 2003-08-07
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 7576
- Registration Number
- NCT00066573
- Locations
- 🇨🇦
Stronach Regional Health Centre at Southlake, Newmarket, Ontario, Canada
🇨🇦Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦Credit Valley Hospital, Mississauga, Ontario, Canada
Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2014-05-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 148
- Registration Number
- NCT00057941
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy
- Conditions
- Interventions
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2018-09-20
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 3104
- Registration Number
- NCT00053898
- Locations
- 🇺🇸
Lynn Regional Cancer Center at Boca Raton Community Hospital - Main Center, Boca Raton, Florida, United States
🇺🇸Aultman Hospital Cancer Center at Aultman Health Foundation, Canton, Ohio, United States
🇺🇸Geisinger Medical Center, Danville, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.